ClinicalTrials.gg
CompletedNCT07309042Updated Sep 23, 2026

Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects

A Phase 1 interventional study of YN001, Rosuvastatin calcium Tablets and YN001, Rosuvastatin calcium Tablets in Atherosclerotic Cardiovascular Diseases and Cerebrovascular Diseases, sponsored by Beijing Inno Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Beijing Inno Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Cerebrovascular Disorders with a site in China — 41 open to participants now, 42 under way, 2 of them phase 3. Cerebrovascular Disorders · China.

Enrollment
51st of 53
24 · median 206
Started
2025
with 15 others
Phase 1
5 of 83
none open now
Registered
78th of 83
by date

Among the 83 studies in Cerebrovascular Disorders with a site in China, this one is the 51st largest by enrollment of the 53 interventional ones that give a count, is one of 16 that started in 2025, is one of 5 in phase 1, and was the 78th registered.

Cerebrovascular Disorders

450 studies on the registry are indexed under Cerebrovascular Disorders; 127 are open to participants now.

Browse Cerebrovascular Disorders studies →

Open to participants now

41 of the 83 studies in Cerebrovascular Disorders with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 94 Cerebrovascular Disorders studies recruiting now, 54 (57%) set no upper age limit and 12 (13%) stop at 75 or younger; 9 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Cerebrovascular Disorders with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the safety and tolerability of YN001 in combination with rosuvastatin, so as to provide evidence for the feasibility of YN001 combined with statins in subsequent clinical trials.

Read the detailed description

The primary objective of this study is to generate the evidence on the safety, tolerability and pharmacokinetic (PK) interaction profile of YN001 when combined with rosuvastatin, a widely prescribed high-intensity statin.

YN001 is being developed for patients with atherosclerotic cardiovascular disease (ASCVD) or at high cardiovascular risk. In these populations, contemporary treatment guidelines recommend statin therapy as foundational background treatment. However, because the human safety and PK profile of YN001 in combination with statins have not yet been established, concomitant statin use has been prohibited in all completed, ongoing, and planned YN001 clinical trials. This restriction creates a clinically and regulatorily important evidence gap: for YN001 to be used in its intended population, it is essential to determine whether co-administration with rosuvastatin is safe and whether either drug's systemic exposure is meaningfully altered.

To address this gap, the present study is designed as a single-centre, randomised, open-label, 3-sequence, 3-period crossover trial in healthy volunteers. The study will evaluate the the safety, tolerability and pharmacokinetics of repeated-dose intravenous YN001 administered alone and in combination with oral rosuvastatin calcium.

A total of 24 subjects will be enrolled. After screening, eligible participants will be randomly allocated 1:1:1 to three cohorts (8 per cohort, target 1:1 sex ratio). Each cohort will undergo three 14-day treatment periods separated by a 7-day wash-out (permissible window ±7 days).

The results of this study will inform whether concomitant statin can be safely permitted in subsequent Phase II and Phase III YN001 clinical trials, thereby enabling evaluation of YN001 in the intended ASCVD and high-cardiovascular-risk populations for whom chronic statin therapy is standard of care.

03

Conditions studied

  • Atherosclerotic Cardiovascular Diseases
  • Cerebrovascular Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the purpose, characteristics, research methods and potential adverse reactions of this study, voluntarily participate in the study as a subject, and sign the Form (ICF) before any assessments are performed.
  2. Healthy Chinese male and female subjects aged 18 to 55 years (inclusive, based on the age at the time of signing the ICF).
  3. Body weight ≥ 50 kg for males and ≥ 45 kg for females; (BMI) ranging from 18 to 28 kg/m² (including the critical values).
  4. Judged by the investigator based on medical history, physical examination, vital signs, 12-lead (ECG), laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) and viral serological test results (normal or abnormal without clinical significance) to be in good general health.
  5. Female subjects must be non-pregnant and non-lactating; female subjects of (including female partners of male subjects) must agree to use effective methods such as abstinence, condoms, intrauterine devices in use, double barrier methods (e.g., condoms plus diaphragms) from the screening period until 6 months after receiving the last dose of the study drug.
  6. Willing and able to comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participation in other clinical trials within 3 months prior to the first dose or within 5 half-lives (whichever is longer). Subjects who withdrew from the study before receiving the study drug (i.e., not administered the drug) are eligible for enrollment.
  2. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health supplements within 2 weeks prior to the first dose, or receipt of any type of vaccination.
  3. Consumption of diets that may affect the in vivo metabolism of drugs (including grapefruit or grapefruit products, pitaya, mango, etc.) within 7 days prior to screening, engagement in strenuous exercise, or consumption of other diets that the investigator deems may affect the absorption, distribution, metabolism, or excretion of drugs.
  4. History of severe food allergies (e.g., anaphylactic shock). Mild food allergies such as lactose intolerance and glucose intolerance are not excluded.
  5. Allergy to multiple drugs, history of allergy to rosuvastatin, or history of allergic reactions to any component of the study drugs.
  6. Known presence of abnormal diseases or factors, including but not limited to clinically significant abnormalities in abdominal color Doppler ultrasound (liver, gallbladder, spleen, pancreas, bilateral kidneys, ureters, urinary bladder), chest posteroanterior radiography, etc.; or clinically significant diseases (including but not limited to diseases of the digestive system, circulatory system, respiratory system, endocrine system, urinary system, immune system, nervous system, and mental and psychological diseases) shown by other clinical findings within 6 months prior to screening.
  7. History of myopathy/myalgia, or predisposition to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, previous combined use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors and fibrates, etc.).
  8. Presence of hypothyroidism or hyperthyroidism.
  9. History of acute or chronic bronchospastic diseases (including asthma, , whether treated or not) or heart failure, myocardial infarction, with a history of onset or recurrence within the past 3 years.
  10. Known history of inflammatory bowel disease, ulcers, gastrointestinal bleeding, or rectal bleeding within 6 months prior to the first dose.
  11. History of pancreatic injury or pancreatitis within 6 months prior to dosing.
  12. Presence of symptoms of urinary tract obstruction or dysuria.
  13. History of autonomic nervous system disorders (e.g., recurrent syncope, palpitations, etc.), with a history of onset or recurrence within the past 3 years.
  14. Suffering from a major unhealed disease within 2 weeks prior to the first dose; or expected to undergo major surgery during the study period.
  15. History of renal impairment, manifested by clinically significant abnormalities in creatinine, blood urea nitrogen (BUN) and/or urea levels, or clinically significant abnormalities in urine components (e.g., proteinuria).
  16. Presence of liver disease or liver injury, or abnormal liver function test results. Subjects who meet any of the following criteria must be excluded from the study:

    1. Any one of (ALT), aspartate aminotransferase (AST), or serum exceeds 1.5 times the (ULN).
    2. Any two or more of ALT, AST, or serum bilirubin exceed the upper limit of normal (ULN).
  17. History of clinically significant (ECG) abnormalities; or presence of any of the following abnormalities during screening or baseline period:

    1. (males) > 470 milliseconds (msec).
    2. QTcF (females) > 480 milliseconds (msec). (Corrected by the Frederica formula, calculated as QTcF = QT/(RR⁰·³³))
  18. Screening test shows level \< 120 grams per liter (g/L) in males and \< 110 grams per liter (g/L) in females.
  19. Blood donation or blood loss exceeding 400 milliliters (mL) within 3 months prior to screening.
  20. Smoking more than 10 cigarettes per day or habitual use of nicotine-containing products within 3 months prior to screening.
  21. History of drug abuse within 12 months prior to screening; or use of any illegal drugs within 3 months prior to screening; or positive results in drug abuse tests (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, morphine, etc.) during screening.
  22. Weekly alcohol consumption exceeding 14 standard drinking units (1 standard drinking unit = 285 mL of beer, or 25 mL of spirits, or 150 mL of wine) within 3 months prior to screening; or consumption of alcohol-containing products within 48 hours prior to the first dose; or positive results in breath alcohol test during the baseline period.
  23. Positive results in tests for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or Treponema pallidum antibody.
  24. The investigator deems the subject unsuitable for participation in the study due to any other diseases or conditions.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    YN001

    Drug: YN001, Rosuvastatin calcium Tablets

  • Other
    YN001+ Rosuvastatin calcium Tablets

    Drug: YN001, Rosuvastatin calcium Tablets

  • Other
    Rosuvastatin calcium Tablets

    Drug: YN001, Rosuvastatin calcium Tablets

Interventions

  • DrugYN001, Rosuvastatin calcium Tablets

    Drug pages: YN001 · Rosuvastatin

    Cycle 1 (Day 1 to day 14) : YN001, 40 mg, once a week, intravenous infusion, administered on day 1 and day 8, for a total of 2 doses. Cycle 2 (days 22 to 35) : YN001, 40 mg, once a week, intravenous infusion, administration on days 22 and 29, for a total of two doses. Rosuvastatin calcium Tablets, 10 mg, once a night, orally. Cycle 3 (Days 43 to 56) : Rosuvastatin calcium Tablets, 10 mg, once a night, orally.

  • DrugYN001, Rosuvastatin calcium Tablets

    Drug pages: YN001 · Rosuvastatin

    Cycle 1 (Day 1 to day 14) : YN001, 40 mg, once a week, intravenous infusion, administered on day 1 and day 8, for a total of two doses. Rosuvastatin calcium Tablets, 10 mg, once a night, oral administration. Cycle 2 (Days 22 to 35) : Rosuvastatin calcium Tablets, 10 mg, once a night, orally. Cycle 3 (days 43 to 56) : YN001, 40 mg, once a week, intravenous infusion, administration of D43 and D50, for a total of two doses.

  • DrugYN001, Rosuvastatin calcium Tablets

    Drug pages: YN001 · Rosuvastatin

    Cycle 1 (Day 1 to day 14) : Rosuvastatin calcium Tablets, 10 mg, once a night, orally. Cycle 2 (Days 22 to 35) : YN001, 40 mg, once a week, intravenous infusion. Cycle 3 (days 43 to 56) : YN001, 40 mg, once a week, intravenous infusion, administration of D43 and D50, for a total of two doses. Rosuvastatin calcium Tablets, 10 mg, once a night, oral administration.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 84 days

Secondary outcomes

  1. Plasma pharmacokinetics: Maximum plasma concentration (Cmax)

    Time frame: 63 days

  2. Number of Participants With ADA

    Time frame: 63 days

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Mar 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 30, 2025
StartActual
Dec 8, 2025
Primary completionActual
Mar 30, 2026
CompletionActual
Mar 30, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309042
Lead sponsor
Beijing Inno Medicine Co., Ltd.
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 8, 2025
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
Sep 23, 2026

Study contacts

Teresa Chen, Master
study director · Beijing Inno Medicine Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: YN001 · Rosuvastatin

Start the discussion